GlassScriptPhysician profile
Shrina Parekh
NPI 1154703270
$1,478.20
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223 · 2020: $19.77 · 2021: $31.49 · 2022: $245 · 2023: $522 · 2024: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $486 · Travel and Lodging: $473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $485.97 |
| Travel and Lodging | $473.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $768.57 | 2023-2024 | Minimed 780g |
| Novo Nordisk INC | $277.34 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $130.03 | 2022-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2022 | |
| Lilly USA, LLC | $76.85 | 2022-2024 | Mounjaro |
| Tandem Diabetes Care, INC. | $28.03 | 2021-2022 | |
| Kyowa Kirin, INC. | $19.27 | 2024 | Crysvita |
| Janssen Biotech, INC. | $19.09 | 2022 | |
| Dexcom, INC. | $17.73 | 2023 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $16.29 | 2023 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shrina Parekh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.